Effects and Safety of Metronidazole in Patients With Gastrectomy
NCT ID: NCT01658852
Last Updated: 2020-09-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE3
INTERVENTIONAL
2011-05-31
2014-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Endoscopic Submucosal Dissection Versus Gastrectomy
NCT02216110
No Antimicrobial Prophylaxis for Laparoscopic Distal Gastrectomy
NCT02200315
Study to Assess the Effect on Recovery of GI Motility and Safety and to Determine the Optimal Dose of LD02GIFRO
NCT01624571
Effect of Erythromycin Before Endoscopy of Patients With Subtotal Gastrectomy (STG), High Risk of Gastric Stasis
NCT01659619
Safety of Laparoscopic Resection for Gastrointestinal Stromal Tumor on Unfavorable Anatomic Site of Stomach
NCT05197933
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Metronidazole
active drug: metronidazole 500mg three time per day for 10 days
metronidazole
Placebo
Placebo three times per day for 10days
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
metronidazole
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* gastrectomy for early gastric cancer with complete resection
* no reccurrence after follow up more than 6 months
* identified small bowel bacterial overgrowth by hydrogen breath test
* symptoms of postgastrectomy syndrome
Exclusion Criteria
* systemic chemotherapy history
* other organic gastrointestinal disease (inflammatory bowel disease, carcinoid syndrome, amyloidosis, intestinal obstruction)
* other gastrointestinal operation history except appendectomy, cholecystectomy)
* recent colonoscopic examination (within 30 days)
* uncontrolled psychopathy
* drug or alcohol abuser
* pregnant or breast feeding woman
* recent history of antibiotics treatment (within 90 days)
* recent history of PPI or H2 blocker treatment (within 30 dyas)
* recent history of probiotics treatment (within 30 dyas)
* recent history of prokinetics or antispasmotic treatment (within 15 days)
* severe systemic illness
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Catholic University of Korea
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Myung-gui Choi
prof.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Gastrectomy-MDZ-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.